Company Overview - The report focuses on Giant Biogene (2367 HK), a company specializing in recombinant collagen-based skincare products and rare ginsenoside-based health supplements [1] - The company is the first globally to achieve mass production of recombinant collagen skincare products and the first in China to obtain a medical device registration certificate for recombinant collagen products [3] - Giant Biogene has a portfolio of 8 major brands with over 100 product SKUs as of the end of 2023 [19] Industry Analysis Recombinant Collagen Market - The recombinant collagen market is expected to grow rapidly, with penetration increasing from 15 9% in 2017 to 62 3% by 2027 [2] - Recombinant collagen offers advantages over animal-derived collagen, including higher bioactivity, better biocompatibility, lower immunogenicity, and easier transportation and storage [13] - The market size for recombinant collagen in functional skincare, medical dressings, and skin rejuvenation is projected to reach 64 5 billion, 25 5 billion, and 12 1 billion yuan respectively by 2027, with a total market size of 108 3 billion yuan [17] Rare Ginsenoside Market - Rare ginsenosides, derived from ginseng, have stronger biological activity and are more easily absorbed by the human body compared to prototype ginsenosides [18] - The market size for rare ginsenoside-based health foods in China is expected to grow from 645 4 million yuan in 2021 to 1 56 billion yuan by 2027 [18] Business Performance - In 2023, the company achieved revenue of 3 52 billion yuan, a 49 05% year-on-year increase, and net profit of 1 45 billion yuan, a 44 59% increase [23] - The flagship brand Kefumei contributed 79 1% of total revenue, growing 72 9% year-on-year to 2 79 billion yuan [23] - The company's gross margin was 84 4% in 2023, with a net profit margin of 41 09% [23] Growth Drivers - The company is expected to obtain two new Class III medical device registrations in 2024 for recombinant collagen liquid and solid formulations, targeting anti-aging applications [4] - The company expanded its production capacity in 2023, adding 2 new recombinant collagen production lines, 4 cosmetic production lines, and 2 medical device production lines [22] - Online sales channels showed strong growth, with Kefumei and Kelijing achieving GMV growth rates exceeding 165% and 70% respectively during the 618 shopping festival [20] Financial Projections - Revenue is forecasted to grow from 4 83 billion yuan in 2024 to 8 07 billion yuan in 2026, representing a CAGR of 29 52% [35] - Net profit is projected to increase from 1 80 billion yuan in 2024 to 2 76 billion yuan in 2026 [35] - EPS is expected to grow from 1 81 yuan in 2024 to 2 78 yuan in 2026 [35] Valuation - The report gives a 6-month target price of 61 54 yuan per share, representing a 21 74% upside from the current price [43] - The company is valued at 24X-35X PE, corresponding to a reasonable valuation range of 43 44-63 35 yuan per share [37] - Using DCF valuation, the intrinsic value per share is estimated at 63 62 yuan [39]

证券研究报告 | 年报点评报告 2024年04月12日 巨子生物（02367.HK） 公司业绩实现亮眼高增，稳步推进妆械协同发展 2023年业绩亮眼，营收/归母净利润分别同增49%/45%。2023年公司实现营业 买入（维持） 收入35.24亿元（yoy+49.0%），实现归母净利润14.52亿元（yoy+44.9%），实 股票信息 现经调整净利润 14.69 亿元（yoy+39.0%）。2023 年公司毛利率为 83.6%，同比 -0.8pcts，主要系销售成本增加及产品结构变化；费用率方面，销售费用率为33.0%， 行业 生物技术 同比+3.1pcts，主要系线上直销渠道快速扩张致营销投入增加；管理费用率为2.7%， 前次评级 买入 同比-2.0pcts，主要系上市费用开支减少；研发费用率为 2.1%，同比+0.2pcts，主 4月11日收盘价(港元) 42.65 要系公司持续投入基础研究与产品研发及研发人员薪酬增加。2023年公司整体经调 总市值(百万港元) 42,436.75 整净利率41.7%，同比-3.0pcts。 总股本(百万股) 995.00 功效性护肤品收入同增69.5%，研发储备驱动品牌势 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Insights - The company reported a revenue of 3.524 billion yuan in 2023, representing a year-on-year growth of 49.05%. The net profit attributable to the parent company was 1.452 billion yuan, up 44.88% year-on-year, with an adjusted net profit of 1.469 billion yuan, reflecting a 39.03% increase. The diluted EPS was 1.48 yuan, marking a 51.02% growth. The company plans to distribute a dividend of 0.44 yuan per share (tax included) and a special dividend of 0.45 yuan per share (tax included) [4][6][9] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 3.524 billion yuan, a 49.05% increase from the previous year. The net profit attributable to the parent company was 1.452 billion yuan, up 44.88%, and the adjusted net profit was 1.469 billion yuan, reflecting a 39.03% increase. The diluted EPS was 1.48 yuan, a growth of 51.02% [4][6][9] - The gross profit margin decreased by 0.76 percentage points to 83.63% due to the expansion of product lines from medical dressings to skincare products [4][5] Product and Brand Performance - The professional skin care segment generated 3.508 billion yuan in revenue, a 51.10% increase, accounting for 99.55% of total revenue. The efficacy skincare products contributed 2.647 billion yuan, growing 69.52% and representing 72.12% of the main business revenue [4][5] - The company's main brand, "可复美," generated 2.788 billion yuan, a 72.86% increase, while "可丽金" saw a slight decline in revenue to 103 million yuan, down 0.29% [4][5] Sales Channels - Direct sales through online DTC channels reached 2.155 billion yuan, a 77.49% increase, accounting for 61.14% of main business revenue. Online e-commerce platforms contributed 178 million yuan, up 42.57% [4][10] - The company has expanded its offline presence, covering approximately 1,500 public hospitals and 2,500 private hospitals and clinics by the end of 2023 [4][5] Future Outlook - The company is expected to achieve revenues of 4.670 billion yuan, 5.927 billion yuan, and 7.451 billion yuan in 2024, 2025, and 2026, respectively, with year-on-year growth rates of 32.51%, 26.93%, and 25.71% [6][9] - The adjusted net profit is projected to be 1.867 billion yuan, 2.192 billion yuan, and 2.657 billion yuan for the same years, with growth rates of 27.10%, 17.45%, and 21.20% [9][13]

证券研究报告 ＃industryId＃ 消费行业 ＃02367.HK ＃巨dy子Com生pa物ny＃ 港股通（沪、深） ＃title＃ ＃investSuggestion＃ ＃ 持续扩充护肤品矩阵，注射产品即将上市 增持 维持 ( ） ＃createTime1＃ 2024年4月3日 投资要点 ＃市场ma数rk据etData＃ ＃ sum直ma销ry＃ 渠道收入快速增长：公司 2023 年收入 35.24 亿元人民币，同比增长 日期 2024.4.2 49.0%，其中DTC线上直销/电商平台线上直销/线下直销/经销商渠道收入 收盘价(港元) 43.85 分 别 为 21.55/1.78/0.89/11.04 亿 元 人 民 币 ， 占 比 分 别 为 总股本(亿股) 9.95 61.2%/5.0%/2.5%/31.3% ， 收 入 分 别 同 比 变 动 总市值(亿港元) 436 +77.5%/+42.7%/+39.6%/+14.6%，DTC线上直销渠道增速主要受益于精细化 总资产(亿元) 49.7 运营下天猫及抖音等渠道成长、精华类产销售等。录得毛利率83.6%，同比 净资产(亿元） 43.7 下降0.8个 ...

%% research.95579.com %% 丨证券研究报告丨 港股研究丨公司点评丨巨子生物（ ） 2367.HK [巨Ta子b生le_物Title] 年年报点评： 2023 业绩超出预期，肌肤焕活产品顺利推进 报告要点 [2T0a2b3le年_S巨um子m生a物ry营] 业收入为35.24亿元，同比增长49%，归母净利润为14.5亿元，同比增长 45%，实现经调净利润 14.7 亿元，同比增长 39%。公司董事会建议派发年末股息 0.44 元/股 （4.37亿元），以及特别股息0.45元/股（4.44亿元），合计8.81亿元。 ...

Investment Rating - The investment rating for the company is "Buy" [3]. Core Views - The company reported a revenue of 3.524 billion yuan, an increase of 49% year-on-year, and a net profit attributable to shareholders of 1.452 billion yuan, up 44.9% [2]. - The company has a strong focus on expanding its cosmetic product line and advancing the approval process for injectable products [2]. - The company maintains a high dividend payout ratio of 61%, with a final dividend of 0.44 yuan per share and a special dividend of 0.45 yuan per share [2]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 35.24 billion yuan (+49%) and a net profit of 14.52 billion yuan (+44.9%) [2]. - Adjusted net profit, excluding share-based payments, was 14.69 billion yuan (+39%) [2]. - The gross margin was 83.6% (-0.8 percentage points), primarily due to the increased proportion of lower-margin cosmetic products [2]. - The net profit margin was 41.2% (-1.2 percentage points) [2]. Product Segments - The "Kefumei" brand saw a revenue increase of 73%, contributing approximately 80% of total revenue [2]. - The "Kailijin" brand experienced a slight decline in revenue by 0.3%, attributed to brand positioning and product strategy adjustments [2]. - The company is actively developing four new skin rejuvenation products and has a broad application space for collagen injectables [2]. Sales Channels - Direct-to-consumer (DTC) sales continued to grow, with DTC online revenue reaching 21.5 billion yuan (+77.5%), accounting for 61% of total revenue [2]. - The company has established a distribution network covering approximately 1,500 public hospitals, 2,500 private clinics, 6,000 chain pharmacies, and 650 CS/KA stores [2]. Future Projections - The company is projected to achieve revenues of 45.9 billion yuan, 57.5 billion yuan, and 69.9 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 30.4%, 25.1%, and 21.6% [6]. - Net profit is expected to grow by 23.8%, 18.9%, and 17.8% for the same years, with corresponding EPS of 1.81, 2.15, and 2.53 yuan [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing rapid growth in its core products, with the launch of injection products imminent [1] - The brand "可复美" has matured in the medical dressing market, continuing to drive sales growth [1] - The company is leading the standardization of recombinant collagen protein, which is expected to benefit from a healthy competitive environment [1] - The upcoming launch of injection products is anticipated to accelerate the market penetration of its three-helix feature products [1] Financial Performance - In 2023, the company achieved revenue of 35.24 billion HKD, a year-on-year increase of 49.0%, and a net profit of 14.52 billion HKD, up 44.9% [1] - Adjusted net profit reached 14.69 billion HKD, reflecting a growth of 39.0% [1] - The core brand "可复美" generated revenue of 27.88 billion HKD, a 72.9% increase, accounting for 79.1% of total revenue [1] - The company expects continued high growth in net profit for 2024-2026, with projections of 19.22 billion HKD, 24.21 billion HKD, and 30.16 billion HKD respectively, representing year-on-year growth rates of 32%, 26%, and 25% [2][3] Product Development - The company has successfully launched multiple new products, including "可复美胶原乳" and "可复美次抛," which have received positive market feedback [1] - The company plans to obtain medical device certifications for two Class III products in mid-2024 and early 2025 [1] Market Position - The company holds a leading position in the recombinant collagen protein market, benefiting from its strong brand recognition and diverse product matrix [2] - The company's two main brands, "可复美" and "可丽金," accounted for over 96% of total revenue in 2023, indicating a strong dual-driver strategy for performance enhancement [1]

浦银国际研究 公司研究 | 消费行业 巨子生物（2367.HK）：品牌及渠道调整 桑若楠，CFA 驱动 2024 年高速增长 浦 消费分析师 银 serena_sang@spdbi.com 在线上渠道布局愈加完善以及可复美收入大幅扩张的背景下，巨子生 国 (852) 2808 6439 物 2023 年收入与净利润增速均高于市场预期。此外，公司首次派息， 际 综合派息率高达 61%。尽管面临高基数的压力中，我们认为公司在可 林闻嘉 丽金品牌调整完毕、线上渠道占比继续提升以及“以爆带新”的经营策 首席消费分析师 略下，公司在2024年仍将保持超指引的高速增长。巨子生物是我们在化 richard_lin@spdbi.com 妆品行业中首选，维持“买入”评级，并上调目标价至52港元。 (852) 2808 6433 公  线上渠道布局与线上营销相辅相成：2023 年，公司大力推进线上渠道 司 2024年3月27日 转化和线上营销运作，带动全年收入和净利润分别同比增长 49%和 研 45%，超市场预期。其中，线上直营收入占比同比提升近10pct 至68.7%。 究 这离不开成功的线上营销的辅助，使主力品牌可复美录得 ...

公司研 究 证 券研究 报 告 日用化学品 2024年03月28日 巨 子生物（02367.HK）2023年报点评 推 荐 （维持） 目标价：50.4港币 大单品方法论初显，看好妆械协同发展 当前价：42.55港元 事项： 华创证券研究所  23年公司实现营收35.24亿元，同比增长49.0%；实现归母净利润14.52亿元， 证券分析师：王薇娜 同比增长44.9%，实现经调整净利润14.69亿元，同比增长39.0%。23年公司 毛利率83.6%，同比略降0.8pct，归母净利率41.2%，同比略降1.0pct，仍维持 电话：010-66500993 相对高位。公司拟派发股息 0.44 元人民币/股（含税），特别股息 0.45 元人民 邮箱：wangweina@hcyjs.com 币/股（含税），综合派息率为61%。 执业编号：S0360517040002 证券分析师：吴晓婵  23下半年营收占比54.4%为19.2亿元，同比增长39.1%；归母净利润7.85亿 元，同比增长39.0%，毛利率83.2%，归母净利率41.6%。 邮箱：wuxiaochan@hcyjs.com 执业编 号：S036052307 ...

公司研究 | 动态跟踪 巨子生物 02367.HK 买入（维持） 业绩超预期，可复美明星单品表现强劲 股价（2024年03月27日） 42.55港元 目标价格 53.16港元 52周最高价/最低价 49.4/28.4港元 总股本/流通H股（万股） 99,500/99,500 H股市值（百万港币） 42,337 核心观点 国家/地区 中国 行业 纺织服装 ⚫ 公司发布2023年业绩公告，实现营业收入35.2亿，同比增长49%，实现归母净利 报告发布日期 2024年03月28日 润14.5亿，同比增长44.9%，其中23H2收入和归母净利润分别增长39.1%和 39%，超市场预期。 1周 1月 3月 12月 ⚫ 明星单品表现优异，可复美品牌驱动业务收入高增。分品牌来看，2023年可复美/ 绝对表现% 1.55 18.52 26.26 -18.64 可丽金/其他品牌收入同比增长72.9%、-0.3%和14.3%，可复美为主要增长驱动， 相对表现% 2.46 20.89 27.66 -2.42 具体来看：1）渠道方面，公司持续拓展线上和线下销售渠道，优化运营策略，使得 恒生指数% -0.91 -2.37 -1.4 - ...